United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
359.58
-0.58 (-0.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
United Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for United Therapeutics stock have an average target of 370.86, with a low estimate of 280 and a high estimate of 600. The average target predicts an increase of 3.14% from the current stock price of 359.58.
Analyst Consensus: Buy
* Price targets were last updated on Nov 1, 2024.
Analyst Ratings
The average analyst rating for UTHR stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 6 | 6 | 6 |
| Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 15 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $243 → $302 | Hold | Maintains | $243 → $302 | -16.01% | Nov 1, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $319 → $344 | Strong Buy | Maintains | $319 → $344 | -4.33% | Oct 31, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $575 → $600 | Buy | Maintains | $575 → $600 | +66.86% | Oct 31, 2024 |
| Argus Research | Argus Research | Strong Buy Maintains $360 → $400 | Strong Buy | Maintains | $360 → $400 | +11.24% | Oct 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $400 → $425 | Strong Buy | Maintains | $400 → $425 | +18.19% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
2.94B
from 2.33B
Increased by 26.32%
Revenue Next Year
3.25B
from 2.94B
Increased by 10.37%
EPS This Year
24.99
from 19.81
Increased by 26.16%
EPS Next Year
28.44
from 24.99
Increased by 13.78%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.1B | 3.5B | 3.8B | |||
| Avg | 2.9B | 3.2B | 3.5B | |||
| Low | 2.8B | 2.8B | 2.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 32.6% | 20.5% | 17.6% | |||
| Avg | 26.3% | 10.4% | 6.4% | |||
| Low | 19.1% | -5.0% | -11.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 27.26 | 36.42 | 33.86 | |||
| Avg | 24.99 | 28.44 | 28.49 | |||
| Low | 21.56 | 22.34 | 16.65 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 37.6% | 45.7% | 19.1% | |||
| Avg | 26.2% | 13.8% | 0.2% | |||
| Low | 8.8% | -10.6% | -41.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.